Blueprint Medicines Corporation

NasdaqGS:BPMC Stock Report

Market Cap: US$8.4b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Blueprint Medicines Future Growth

Future criteria checks 6/6

Blueprint Medicines is forecast to grow earnings and revenue by 60.8% and 21.1% per annum respectively. EPS is expected to grow by 61.4% per annum. Return on equity is forecast to be 29.3% in 3 years.

Key information

60.8%

Earnings growth rate

61.38%

EPS growth rate

Biotechs earnings growth23.0%
Revenue growth rate21.1%
Future return on equity29.27%
Analyst coverage

Good

Last updated07 Jul 2025

Recent future growth updates

Recent updates

Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade

Jun 18
User avatar

Expanding Patient Reach And Pipeline Development Will Unlock Potential

Strong AYVAKIT demand, expanded market reach, and improved therapy duration fuel revenue growth and enhance operating margin stability.

There's Reason For Concern Over Blueprint Medicines Corporation's (NASDAQ:BPMC) Massive 28% Price Jump

May 04
There's Reason For Concern Over Blueprint Medicines Corporation's (NASDAQ:BPMC) Massive 28% Price Jump

Blueprint Medicines: Strong Business, Ambitious Targets, Expensive Stock

Mar 29

Is Blueprint Medicines (NASDAQ:BPMC) A Risky Investment?

Mar 07
Is Blueprint Medicines (NASDAQ:BPMC) A Risky Investment?

Revenues Not Telling The Story For Blueprint Medicines Corporation (NASDAQ:BPMC) After Shares Rise 28%

Jan 24
Revenues Not Telling The Story For Blueprint Medicines Corporation (NASDAQ:BPMC) After Shares Rise 28%

Blueprint Medicines: Growth For The Long Term Still Mostly Priced In

Sep 27

Blueprint Medicines: Overdue For A Breather

Jul 16

Blueprint Medicines: Rampant Growth Mostly Priced In

May 04

Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)

Feb 20

Earnings and Revenue Growth Forecasts

NasdaqGS:BPMC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,17123819432015
12/31/2026956727211319
12/31/2025721-44-65-19719
3/31/2025562-156-151-146N/A
12/31/2024509-67-197-193N/A
9/30/2024434-128-251-242N/A
6/30/2024363-205-348-333N/A
3/31/2024282-288-430-415N/A
12/31/2023249-507-453-437N/A
9/30/2023216-555-492-479N/A
6/30/2023226-554-515-505N/A
3/31/2023205-581-503-493N/A
12/31/2022204-558-511-502N/A
9/30/2022272-718-404-395N/A
6/30/2022230-702-367-361N/A
3/31/2022221-650-310-306N/A
12/31/2021180-644-302-299N/A
9/30/2021107-411-312-309N/A
6/30/2021828340407409N/A
3/31/2021809325369371N/A
12/31/2020794314384387N/A
9/30/2020811333361367N/A
6/30/202075-395-340-327N/A
3/31/202072-371-321-307N/A
12/31/201967-348-292-278N/A
9/30/201916-362-311-301N/A
6/30/20198-340-291-284N/A
3/31/201944-267-214-206N/A
12/31/201845-237N/A-175N/A
9/30/201845-205N/A-142N/A
6/30/201852-170N/A-114N/A
3/31/201817-177N/A-138N/A
12/31/201721-148N/A-120N/A
9/30/201727-120N/A-104N/A
6/30/201726-99N/A-96N/A
3/31/201727-85N/A-86N/A
12/31/201628-72N/A-25N/A
9/30/201625-67N/A-19N/A
6/30/201622-63N/A-13N/A
3/31/201618-58N/A-6N/A
12/31/201511-56N/A-32N/A
9/30/20157-57N/A-30N/A
6/30/20153-56N/A-26N/A
3/31/20151-52N/A-24N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BPMC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: BPMC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BPMC is expected to become profitable in the next 3 years.

Revenue vs Market: BPMC's revenue (21.1% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: BPMC's revenue (21.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BPMC's Return on Equity is forecast to be high in 3 years time (29.3%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/17 01:02
End of Day Share Price 2025/07/17 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Blueprint Medicines Corporation is covered by 10 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George FarmerBMO Capital Markets Equity Research
Dane LeoneBTIG
Arlinda LeeCanaccord Genuity